RRISC Study: Reduction of Restenosis In Saphenous Vein Grafts With Cypher Sirolimus-Eluting Stent.

Antwerp Cardiovascular Institute Middelheim

Status and phase: Completed; Phase 2

Conditions: Coronary Artery Disease; Unstable Angina; Stable Angina; Saphenous Vein Graft Disease

Treatments: Device: sirolimus-eluting stent; Device: bare metal stent

Study type: Interventional

Funder types: Other

Identifiers

NCT00263263

INCUBATE-001

Details and patient eligibility

About

Context: Sirolimus-eluting-stents have improved the benefits of percutaneous interventions in native coronary arteries reducing the occurrence of restenosis and repeated revascularization, however saphenous vein grafts have been always excluded form randomized trials.

Objective: To evaluate the angiographic and clinical impact of sirolimus-eluting-stents with respect to bare-metal-stents in degenerated vein grafts.

Design: Double-blind randomized controlled non-industry-sponsored trial.

Setting: A single-center tertiary-care referral hospital.

Patients: All patients are randomly allocated to sirolimus-eluting-stent implantation or the corresponding bare-metal-stent. All patients are followed clinically and repeated angiographic follow-up is performed in all at 6-months.

Main outcome measure: Primary end-point is 6-months angiographic in-stent late loss. Secondary end-points include: binary angiographic in-stent and in-segment restenosis, intravascular-ultrasound-measured neo-intimal hyperplasia volume and all the clinical events (death, myocardial infarction, target-lesion and target-vessel revascularization).

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 to 85 years-old
• clear signs and/or symptoms of stable or unstable angina or documented silent ischemia
• one or more de-novo target lesions (>50% diameter stenosis by visual estimate) localized in one or more diseased SVG with a reference vessel diameter (RVD) included between 2.5 and 4.0 mm (by visual estimate)
• signed informed consent.

Exclusion criteria

• Myocardial Infarction within the previous 7 days
• documented left ventricular ejection fraction <25%
• impaired renal function (creatinine >3.0 mg/dl) at the time of treatment
• outflow obstruction of the graft due to distal anastomotic stenosis
• totally occluded Saphenous Vein Graft
• brachytherapy treatment in the index vessel before enrollment
• life expectancy less than 12 months
• known allergy to aspirin, clopidogrel bisulfate, heparin, stainless steel, contrast agent or sirolimus
• hemorrhagic diatheses
• a recent positive pregnancy test, breast-feeding, or the possibility of a future pregnancy.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind